Ocimum Gets Up to $17M Capital Investment, Closes Gene Logic Genomics Biz Buy | GenomeWeb
NEW YORK (GenomeWeb News) – Ocimum Biosolutions has landed an equity investment of up to $17 million and has closed its acquisition of Gene Logic’s genomics division, the company said today.
 
The capital investment came from Kubera Cross Border Fund, as well as affiliates of Kubera Partners, which manages KUBC.
 
Ocimum said that the acquired genomics business will retain the Gene Logic name and will continue operating out of Gaithersburg, Md.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.